Adrenoceptors in the Lower Urinary Tract.

Akiyama K et al (1999) KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 291(1):81–91

Akiyama K et al (2001) Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 8(4):177–183

Alexandre EC et al (2016) Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J Pharmacol 173(3):415–428

Andersson K-E, Michel MC (2011) Urinary tract. In: Hofmann FB (ed) Handbook of experimental pharmacology, vol 202. Springer Verlag, Heidelberg, p 577

Aro E et al (2015) Is there a peripheral site of action contributing to the voiding effects of alpha(2)-adrenoceptor agonists and antagonists? World J Urol 33(3):433–440

Azuma H et al (1989) Alpha 1-adrenoceptor antagonist activity of novel pyrimidine derivatives (SHI437 and IK29) in rabbit aorta and trigone of the bladder. Br J Pharmacol 96(4):1000–1006

Barendrecht MM et al (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95(Suppl 4):19–28

Barendrecht MM et al (2008) Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27(3):226–230

Barendrecht MM et al (2009) The effect of bladder outlet obstruction on α

Benson GS et al (1976) Adrenergic and cholinergic stimulation and blockade of the human bladder base. J Urol 116(2):174–175

Boyd K, Hilas O (2014) alpha-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Ann Pharmacother 48(6):711–722

Boyle P et al (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58(5):717–722

Brahmadevara N, Shaw AM, MacDonald A (2004) ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 142(4):781–787

Buono R et al (2014) Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. Eur J Pharmacol 744:42–51

Calmasini FB et al (2015) The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication? Prostate 75(4):440–447

Campschroer T et al (2018) α-blockers as medical expulsive therapy for ureteric stones: a Cochrane systematic review. BJU Int 122(6):932–945

Canda AE et al (2007) Physiology and pharmacology of the human ureter: basis for current and future treatments. Urol Int 78:289–298

Cernecka H, Sand C, Michel MC (2014) The odd sibling: features of ß

Chapple C (2011) Overview on the lower urinary tract. Handb Exp Pharmacol 202:1–14

Chapple CR et al (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59(3):342–352

Chapple CR et al (2014) Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 33(1):17–30

Costantini E et al (2009) Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urol Int 83(3):311–315

Cui Y et al (2021) Trigonal-sparing vs. trigonal-involved onabotulinumtoxinA injection for the treatment of overactive bladder: a systematic review and meta-analysis. Front Neurol 12:651635

Dale PR et al (2014) The pharmacological rationale for combining muscarinic receptor antagonists and ß-adrenoceptor agonists in the treatment of airway and bladder disease. Curr Opin Pharmacol 16C:31–42

Dallanoce C et al (2007) Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes. Bioorg Med Chem 15(7):2533–2543

Danuser H et al (2001) Systemic and topical drug administration in the pig ureter: effect of phosphodiesterase inhibitors α1, ß and ß2-adrenergic receptor agonists and antagonists on the frequency and amplitude of ureteral contractions. J Urol 166(2):714–720

Deplanne V, Galzin AM (1996) Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther 278(2):527–534

Djavan B et al (2004) Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 64(6):1144–1148

Erdogan BR et al (2022a) Validation of fenoterol to study β

Erdogan BR et al (2022b) Established and emerging treatments for diabetes-associated lower urinary tract dysfunction. Naunyn Schmiedeberg’s Arch Pharmacol 395(8):887–906

Eredics K, Madersbacher S, Schauer I (2017) A relevant midterm (12 months) placebo effect on lower urinary tract symptoms and maximum flow rate in male lower urinary tract symptom and benign prostatic hyperplasia – a meta-analysis. Urology 106:160–166

Feve B et al (1991) Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. J Biol Chem 266(30):20329–20336

Fry CH et al (2010a) Animal models and their use in understanding lower urinary tract dysfunction. Neurourol Urodyn 29(4):603–608

Fry CH, Meng E, Young JS (2010b) The physiological function of lower urinary tract smooth muscle. Auton Neurosci 154(1–2):3–13

Furuta A et al (2015) Noradrenergic mechanisms controlling urethral smooth and striated muscle function in urethral continence reflex in rats. Low Urin Tract Symptoms 7(3):155–161

Fusco F et al (2016) a

Gacci M et al (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 11(6):1554–1566

Goepel M et al (1997) Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 25:199–206

Haynes JM (2007) beta(2) and beta(3)-adrenoceptor inhibition of alpha(1)-adrenoceptor-stimulated Ca(2+) elevation in human cultured prostatic stromal cells. Eur J Pharmacol 570(1–3):18–26

Hennenberg M (2022) Pharmacology of the prostate in non-infectious diseases. In: Kenakin T (ed) Comprehensive pharmacology, 1st edn. Elsevier, pp 708–744

Hennenberg M et al (2011a) beta-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of alpha1A-adrenoceptors. World J Urol 29(2):157–163

Hennenberg M et al (2011b) alpha1-adrenoceptor activation induces phosphorylation of beta2-adrenoceptors in human prostate tissue. BJU Int 108(6):922–928

Hennenberg M et al (2013a) The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol 305(10):F1383–F1390

Hennenberg M et al (2013b) Noradrenaline induces binding of clathrin light chain A to alpha1-adrenoceptors in the human prostate. Prostate 73(7):715–723

Hennenberg M, Stief CG, Gratzke C (2014) Prostatic alpha1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn 33(7):1074–1085

Hennenberg M et al (2016) Inhibition of adrenergic and non-adrenergic smooth muscle contraction in the human prostate by the phosphodiesterase 10-selective inhibitor TC-E 5005. Prostate 76(15):1364–1374

Hennenberg M et al (2017a) Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. Eur J Pharmacol 803:39–47

Hennenberg M et al (2017b) Non-adrenergic, tamsulosin-insensitive smooth muscle contraction is sufficient to replace alpha1 -adrenergic tension in the human prostate. Prostate 77(7):697–707

Herlemann A et al (2018) Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. Am J Physiol Renal Physiol 314(1):F47–F57

Herschorn S et al (2017) Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 120(4):562–575

Hoffstedt J et al (1996) Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord 20(5):428–434

Honda K, Nakagawa C (1986) Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 239(2):512–516

Honda K, Miyata-Osawa A, Takenaka T (1985) alpha 1-adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmiedeberg’s Arch Pharmacol 330(1):16–21

Huang R et al (2021) Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate. Front Pharmacol 12:666047

Huang R et al (2022) Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983. Prostate 82(1):59–77

Igawa Y, Aizawa N, Michel MC (2019) β

Kalodimos PJ, Ventura S (2001) Beta2-adrenoceptor-mediated inhibition of field stimulation induced contractile responses of the smooth muscle of the rat prostate gland. Eur J Pharmacol 431(1):81–89

Kanie S et al (2012) Pharmacological effect of TRK-380, a novel selective human beta3-adrenoceptor agonist, on mammalian detrusor strips. Urology 79(3):744 e1–7

Kedia GT et al (2013) Pharmacologic characterization of human male urethral smooth muscle: an in vitro approach. Urology 82(6):1451 e13–9

Kitazawa T (2013) Contractile signaling pathways in mouse prostate smooth muscle. Prostate 73(9):996–1006

Kobayashi S et al (2009) Gene expression and mechanical functions of α

Krauwinkel W et al (2012) Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34(10):2144–2160

Kummeling MT et al (2020) Initial report on distribution of beta3-adrenoceptor in the human female urethra. Neurourol Urodyn 39(1):125–132

Kurizaki Y et al (2013) Relationship between expression of ß

Kwon SY et al (2020) Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: a prospective study. Investig Clin Urol 61(4):419–424

Kyprianou N, Vaughan TB, Michel MC (2009) Apoptosis induction by doxazosin and other quinazoline α

Labadia A et al (1987) Alpha- and beta-adrenergic receptors in the horse ureter. Rev Esp Fisiol 43(4):421–425

Leblais V et al (2004) Role of alpha-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. J Pharmacol Exp Ther 309(1):137–145

Lefevre-Borg F et al (1993) Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 109(4):1282–1289

Lepor H (2004) Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 6(Suppl 9):S3–S10

Lepor H, Kazzazi A, Djavan B (2012) alpha-blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol 22(1):7–15

Li B et al (2020a) Inhibition of neurogenic and thromboxane A2 -induced human prostate smooth muscle contraction by the integrin alpha2beta1 inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22. Prostate 80(11):831–849

Li B et al (2020b) Regulation of smooth muscle contraction by monomeric non-RhoA GTPases. Br J Pharmacol 177(17):3865–3877

Liao CH, Kuo HC (2018) Mirabegron 25 mg monotherapy is safe but less effective in male patients with overactive bladder and bladder outlet obstruction. Urology 117:115–119

Lightner DJ et al (2019) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol 202(3):558–563

Lim I, Chess-Williams R (2022) Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism. Naunyn Schmiedeberg’s Arch Pharmacol 395(7):839–847

Markiewicz W et al (2014) The influence of doxazosin, an alpha1-adrenergic receptor antagonist on the urinary bladder contractility in pigs. Pol J Vet Sci 17(3):527–529

Markiewicz W et al (2017) The influence of doxazosin on the contractility of the urinary bladder in female pigs with experimentally induced cystitis. Pol J Vet Sci 20(3):485–490

Mastrangelo D, Iselin CE (2007) Urothelium dependent inhibition of rat ureter contractile activity. J Urol 178(2):702–709

Matsumoto R et al (2013) Expression and functional role of ß

McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398

McLeod DG, Reynolds DG, Swan KG (1973) Adrenergic mechanisms in the canine ureter. Am J Phys 224(5):1054–1058

Mehta RC et al (2000) Biochemical and functional characterization of 1-benzyl substituted trimetoquinol affinity analogs on rat and human beta-adrenoceptors. Biochem Pharmacol 59(5):517–529

Meyer LE, Brown JN (2012) Tamsulosin for voiding dysfunction in women. Int Urol Nephrol 44(6):1649–1656

Michel MC (2011) beta-adrenergic receptor subtypes in the urinary tract. Handb Exp Pharmacol 202:307–318

Michel MC (2014) Do ß-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder? Naunyn Schmiedeberg’s Arch Pharmacol 387(3):215–224

Michel MC (2020) α

Michel MC (2023) Are β3-adrenoceptor gene polymorphisms relevant for urology? Neurourol Urodyn 42(1):33–39

Michel MC, de la Rosette JJMCH (2004) Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother 5(1):151–160

Michel MC, de la Rosette JJMCH (2006) α-Blocker treatment of urolithiasis. Eur Urol 50(2):213–214

Michel MC, Gravas S (2016) Safety and tolerability of ß

Michel MC, Staskin D (2022) Study designs for evaluation of combination treatment: focus on individual patient benefit. Biomedicine 10(2):270

Michel MC, Vrydag W (2006) α

Michel MC et al (1998) Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1(6):332–335

Michel MC, Oelke M, Peters SLM (2005) The neuro-urological connection. Eur Urol Suppl 4(1):18–28

Michel MC et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. In press

Miyatake R et al (2001) Effects of isoproterenol and butylscopolamine on the friction between an artificial stone and the intraureteral wall in anaesthetized rabbits. J Urol 166(3):1083–1087

Mo W et al (2017) The β

Monneron MC et al (2000) In vitro alpha-adrenoceptor autoradiography of the urethra and urinary bladder of the female pig, cat, Guinea-pig and rat. Scand J Urol Nephrol 34(4):233–238

Musselman DM et al (2004) A randomized crossover study to evaluate Ro 115-1240, a selective α

Nergardh A, Boreus LO, Naglo AS (1977) Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol 40(1):14–21

Nickel JC, Sander S, Moon TD (2008) A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62(10):1547–1559

Nishimatsu H et al (1999) Contractile responses to alpha1-adrenoceptor agonists in isolated human male and female urethra. BJU Int 84(4):515–520

Nitti V et al (2013a) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189(4):1388–1395

Nitti VW et al (2013b) Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 190(4):1320–1327

Noda K et al (2002) Functional role of inhibitory and excitatory nerves in the porcine lower urinary tract. Eur J Pharmacol 456(1–3):81–90

Oelke M et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140

Oger S et al (2009) Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 6(3):836–847

Oger S et al (2010) Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 57(4):699–707

Ohlstein EH, von Keitz A, Michel MC (2012) A multicenter, double-blind, randomized, placebo controlled trial of the ß 3 -adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62(5):834–840

Oostendorp J et al (2000) Contribution of ß-adrenoceptor subtypes to relaxation of colon and oesophagus and pacemaker activity of ureter in wild-type and ß

Park YC et al (2000) Existence of a ß3-adrenoceptor and its functional role in the human ureter. J Urol 164(4):1364–1370

Reitz A et al (2004) The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur Urol 46(2):235–240. discussion 240

Robinson D et al (2007) A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 100(4):840–845

Roehrborn CG (2006) Three months’ treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9(2):121–125

Roehrborn CG et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179(2):616–621. discussion 621

Roehrborn CG et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123–131

Roosen A et al (2008) Synergistic effects in neuromuscular activation and calcium-sensitization in the bladder trigone. BJU Int 101(5):610–614

Roosen A et al (2009a) Adreno-muscarinic synergy in the bladder trigone: calcium-dependent and -independent mechanisms. Cell Calcium 45(1):11–17

Roosen A et al (2009b) Clinical and experimental aspects of adreno-muscarinic synergy in the bladder base and prostate. Neurourol Urodyn 28(8):938–943

Saban MR et al (2002) Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen stimulation. Am J Pathol 160(6):2095–2110

Sakalis V et al (2021) The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. Cent European J Urol 74(3):388–421

Schneider T, Michel MC (2010) Can [

Schwinn DA, Roehrborn CG (2008) Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15(3):193–199

Scofield MA et al (1995) Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. J Pharmacol Exp Ther 275:1035–1042

Sellers D, Chess-Williams R, Michel MC (2018) Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. Naunyn Schmiedeberg’s Arch Pharmacol 391(7):675–694

Shapiro E, Tsitlik JE, Lepor H (1987) Alpha 2 adrenergic receptors in canine prostate: biochemical and functional correlations. J Urol 137(3):565–570

Sigala S et al (2004) Alpha1 adrenoceptor subtypes in human urinary bladder: sex and regional comparison. Life Sci 76(4):417–427

Speakman MJ, Walmsley D, Brading AF (1988) An in vitro pharmacological study of the human trigone–a site of non-adrenergic, non-cholinergic neurotransmission. Br J Urol 61(4):304–309

Spek A et al (2021) Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists. Naunyn Schmiedeberg’s Arch Pharmacol 394(6):1113–1131

Staskin D et al (2020) International phase III, randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204(2):316–324

Streng T, Santti R, Andersson KE (2010) Voiding effects mediated by alpha2-adrenoceptors in the anaesthetized male rat. BJU Int 106(10):1546–1549

Strittmatter F et al (2011) Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol 650(2–3):650–655

Suzuki T et al (2016) The expression of beta3-adrenoceptors and their function in the human prostate. Prostate 76(2):163–171

Takahashi R et al (2007) RhoA/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn 26(4):547–551

Takeda H et al (2003) Functional characterization of beta-adrenoceptor subtypes in the canine and rat lower urinary tract. J Urol 170(2 Pt 1):654–658

Tamalunas A et al (2021a) Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction. Life Sci 281:119771

Tamalunas A et al (2021b) Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: a novel remedy in LUTS? Prostate 81(7):377–389

Tasler S et al (2012) An aryloxypropanolamine hbeta3-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharm Sci 46(5):381–387

Tatemichi S et al (2006) Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodyn 25(7):792–799. discussion 800–801

Tatemichi S et al (2012) Comparison of the effects of four alpha1-adrenoceptor antagonists on ejaculatory function in rats. Urology 80(2):486 e9–16

Teixeira CE et al (2007) Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract. Biochem Pharmacol 74(4):647–658

Thiagamoorthy G, Cardozo L, Robinson D (2016) Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother 17(10):1317–1325

Tomiyama Y et al (2003a) Pharmacological profile of KUL-7211, a selective ß-adrenoceptor agonist, in isolated ureteral smooth muscle. J Pharmacol Sci 92(4):411–419

Tomiyama Y et al (2003b) Comparison between CL-316243- and CGP-12177A-induced relaxations in isolated canine ureter. Pharmacology 68(3):140–146

Tzortzis V et al (2009) Medical expulsive therapy for distal ureteral stones. Drugs 69(6):677–692

Ueda S, Satake N, Shibata S (1984) Alpha 1- and alpha 2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra. Eur J Pharmacol 103(3–4):249–254

Uhlen M et al (2015) Tissue-based map of the human proteome. Science 347(6220):1260419

Van der Graaf PH et al (1997) Analysis of alpha1-adrenoceptors in rabbit lower urinary tract and mesenteric artery. Eur J Pharmacol 327(1):25–32

van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66(3):287–301

Villa L et al (2013) Effects of silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters. Br J Pharmacol 169(1):230–238

Walden PD et al (1997) Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 157(3):1032–1038

Walther S et al (2018) Adreno-muscarinic synergy in the male human urinary outflow tract. Neurourol Urodyn 37(7):2128–2134

Wanajo I et al (2004) Pharmacological characterization of ß-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle. J Urol 172(3):1155–1159

Wang X et al (2020) Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by alpha1-blockers. Eur J Pharmacol 873:172985

Weiss RM, Basset AL, Hoffman BF (1978) Adrenergic innervation of the ureter. Investig Urol 16(2):123–127

White CW, Short JL, Ventura S (2013) Rho kinase activation mediates adrenergic and cholinergic smooth muscle contractile responses in the mouse prostate gland. Eur J Pharmacol 721(1–3):313–321

White CW et al (2019) What makes the α

Wuest M et al (2009) Catecholamines relax detrusor through ß

Wuest M et al (2011) The muscarinic receptor antagonist propiverine exhibits alpha(1)-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol 29(2):149–155

Yamanishi T et al (2003) Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn 22(4):338–342

Yanagisawa T et al (2000) Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells. Tohoku J Exp Med 192(3):181–193

Yanase H et al (2008) The involvement of urothelial alpha1A adrenergic receptor in controlling the micturition reflex. Biomed Res 29(5):239–244

Yoshida M et al (2018) Vibegron, a novel potent and selective b

Zhang HL et al (2017) Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Int J Impot Res 29(4):148–156

Adrenoceptors in the Lower Urinary Tract.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Martin Hennenberg (M)

Martin C Michel (MC)

Classifications MeSH